POMALYST ®
Pomalyst is an immunomodulatory agent, a drug that can modify, enhance, or suppress the functioning of the immune system.
Indications for the use of Pomalyst
Pomalyst was approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least 2 prior therapies, including the immunomodulatory agent Revlimid® (lenalidomide) and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Combination therapies with Pomalyst
¡ Pomalyst + dexamethasone [ Pd ]
¡ Cyclophosphamide + Pd [ PCd ]
¡ Darzalex® (daratumumab) infusion + Pd [ DPd ]
¡ Darzalex Faspro® (daratumumab + hyaluronidase-fihj) injection + Pd [ DPd ]
¡ Empliciti® (elotuzumab) + Pd [ EPd ]
¡ Kyprolis® (carfilzomib) + Pd [ KPd ]
¡ Ninlaro® (ixazomib) + Pd [ IPd ]
¡ Sarclisa® (isatuximab-irfc) + Pd [ Isa-Pd ]
¡ Velcade® (bortezomib) + Pd [ PVd ]
¡ Xpovio® (selinexor) + Pd [ XPd ]
Administration of Pomalyst
Pomalyst is taken by mouth in the form of a a capsule with a dose of 2 mg to 4 mg on days 1 through 21 of repeated 28-day Cycles until disease progression. Pomalyst should be swallowed with water at the same time of the day, with or without food.
Special cautions with Pomalyst
¡ Pomalyst is present in the semen of male patients who take it. Female partners of male patients who take Pomalyst and female patients of reproductive potential must comply with mandatory contraceptive measures. Nursing mothers should decide whether to discontinue nursing or to discontinue Pomalyst.
¡ Patients must receive a risk assessment to determine which antithrombotic medication is appropriate to reduce the risk of blood clots forming and growing.
¡ Smoking may reduce the efficacy of Pomalyst.
Possible side effects of Pomalyst
You must promptly report any unwanted or unexpected side effect or reaction to your doctor, who may adjust your dose of Pomalyst, interrupt your treatment until your side effect resolves, or prescribe additional medication. Side effects of Pomalyst may include the following:
¡ Low blood cell counts
¡ Unusual tiredness or physical weakness
¡ Nausea
¡ Back pain
¡ Increased risk of blood clots
¡ Neuropathy
¡ Upper respiratory tract infection or pneumonia
¡ Constipation
¡ Diarrhea
¡ Fever
¡ Dizziness and confusion
¡ Shortness of breath
For more information about Pomalyst, use the QR code below to read the IMF’s booklet Understanding POMALYST® (pomalidomide).
As always, the IMF urges you to discuss all medical issues with your doctor and to contact the IMF InfoLine with your myeloma-related questions and concerns at 1.818.487.7455 or infoline@myeloma.org. International Myeloma Foundation 4400 Coldwater Canyon Avenue #300 – Studio City, CA 91604 1.818.487.7455 TheIMF@myeloma.org myeloma.org